Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

News Release: New achievement towards the combination of Essilor and Luxottica - Hive-down of Essilor's activities


Posted on: 12 Oct 17

New achievement towards the combination of Essilor and Luxottica
Hive-down of Essilor's activities

PDF Version of the news release

Charenton-le-Pont, France (October 12, 2017 - 8:30 a.m.) - On October 3, 2017, the Board of Directors of Essilor International (Compagnie Générale d'Optique) («Essilor») confirmed that the hive-down of Essilor's activities is expected to be completed by the end of 2017. The hive-down was previously approved by Essilor's shareholders during the general shareholders' meeting held on May 11, 2017.

Pursuant to this hive-down, Essilor will contribute its activities and equity holdings to one of its subsidiaries (formerly named Delamare Sovra) which has been renamed "Essilor International[1]" and which will carry on the operational activities currently performed by Essilor.
The hive-down of Essilor's activities is a condition precedent to the contribution by Delfin of its Luxottica shares to Essilor.

Once the other conditions precedent to complete the contribution of the Luxottica shares to Essilor are satisfied, Essilor will be renamed «EssilorLuxottica» and will become a holding company at the top of the combined group, holding Essilor International and Luxottica.

The governance of Essilor International will be similar to the current governance of Essilor. Mr. Hubert Sagnières will be Chief Executive Officer (Président) of the company, and Mr. Laurent Vacherot will be Deputy Chief Executive Officer (Directeur Général Délégué).

The hive-down constitutes another significant step towards the completion of the combination of Essilor and Luxottica.



[1]Since October 3, 2017, the beneficiary company Essilor International (which is the new corporate name of "Delamare Sovra") is a French simplified joint-stock company (société par actions simplifiée), whose registered office is located at 147, rue de Paris, 94227 Charenton-le-Pont Cedex, France. It is registered with the Trade and Companies Registry (Registre du Commerce et des Sociétés) of Créteil under number 439 769 654.


Further information
For further information on the hive-down, please refer to the hive-down agreement (projet de traité d'apport partiel d'actif), dated March 27, 2017, by and between Essilor and Delamare Sovra (which has been renamed "Essilor International"), which was filed with the Trade and Companies Registries (Registres du Commerce et des Sociétés) of Créteil and Versailles and published on Essilor's website
(https://www.essilor.com/en/investors/annual-shareholders-meeting/combined-general-shareholders-meeting-may-11-2017/). 

For further information on the contribution by Delfin of its Luxottica shares to Essilor, please refer to the contribution agreement (projet de traité d'apport partiel d'actif), dated March 22, 2017, by and between Essilor and Delfin S.à r.l., which was filed with the Trade and Companies Registry (Registre du Commerce et des Sociétés) of Créteil and published on Essilor's website
(https://www.essilor.com/en/investors/annual-shareholders-meeting/combined-general-shareholders-meeting-may-11-2017/), as well as the "Document E", filed on April 7, 2017 with the French Autorité des marchés financiers under number E. 17-014 and published on Essilor's website (https://www.essilor.com/en/investors/annual-shareholders-meeting/combined-general-shareholders-meeting-may-11-2017/).  

About Essilor
Essilor International (Compagnie Générale d'Optique) («Essilor») is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, EyezenTM, Xperio®, Foster Grant®, BolonTM and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of more than €7.1 billion in 2016 and employs approximately 64,000 people worldwide. It markets its products in more than 100 countries and has 33 plants, 490 prescription laboratories and edging facilities, as well as 5 research and development centers around the world (as of December 31, 2016). For more information, please visit www.essilor.com.
Essilor is a French joint-stock company (société anonyme), with a share capital of €39,343,430.16, whose registered office is at 147, rue de Paris, 94220 Charenton-le-Pont, France, and registered with the Trade and Companies Registry (Registre du Commerce et des Sociétés) of Créteil under number 712 049 618.
The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. 
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

CONTACTS

Investor Relations
Véronique Gillet
Tel.: +33 (0)1 49 77 42 16
Corporate Communications
Lucia Dumas
Tel.: +33 (0)1 49 77 45 02

 
Media Relations
Maïlis Thiercelin
Tel.: +33 (0)1 49 77 45 02

 

Important information
This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or any other jurisdiction. Securities may not be offered or sold in the United States unless they have been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or are exempt from registration. The securities that may be offered in any transaction have not been and will not be registered under the U.S. Securities Act and Essilor does not intend to make a public offering of any such securities in the United States.
This press release is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). The securities which are referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/2669ca09-3c84-4d2b-b11a-972cd03cce91

GlobeNewswire
globenewswire.com

Last updated on: 12/10/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.